Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

P(RNCH(2)CH(2))(3)N: efficient 1,4-addition catalysts.

Philip B Kisanga1, Palanichamy Ilankumaran, Brandon M Fetterly

  • 1Department of Chemistry, Gilman Hall, Iowa State University, Ames, IA 50011, USA.

The Journal of Organic Chemistry
|May 25, 2002
PubMed
Summary

Catalytic amounts of nonionic strong bases facilitate the 1,4-addition of alcohols, nitroalkanes, and Schiff bases to unsaturated compounds. This method offers moderate to excellent yields and easy catalyst removal, enhancing synthetic efficiency.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.

Nature medicine·2023
Same author

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.

Blood·2022
Same author

Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room Temperature.

Clinical pharmacology in drug development·2022
Same author

ROAR trial: which treatment is effective after progression? - Authors' reply.

The Lancet. Oncology·2022
Same author

Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors.

Clinical pharmacology in drug development·2022
Same author

Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.

The Lancet. Oncology·2021

Area of Science:

  • Organic Chemistry
  • Catalysis
  • Synthetic Methodology

Background:

  • 1,4-addition reactions are fundamental in organic synthesis.
  • Developing efficient and selective catalytic systems remains a key challenge.
  • Nonionic strong bases offer unique reactivity and handling properties.

Purpose of the Study:

  • To explore the utility of novel nonionic strong bases as catalysts for 1,4-addition reactions.
  • To investigate the scope and efficiency of these catalysts with various nucleophiles and electrophiles.
  • To evaluate the diastereoselectivity of the addition reactions, particularly with Schiff's bases.

Main Methods:

  • Utilized catalytic amounts of phosphazene bases (P(RNCH2CH2)3N) in isobutyronitrile.
  • Reacted primary alcohols, higher nitroalkanes, and Schiff's bases of alpha-amino esters with alpha,beta-unsaturated substrates.

Related Experiment Videos

  • Conducted reactions at temperatures ranging from -63 to 70 degrees C.
  • Analyzed product yields and diastereoselectivity, focusing on the anti product.

    • Main Results:

    • Achieved moderate to excellent yields for the 1,4-addition products.
    • Demonstrated high diastereoselectivity for the anti product when using Schiff's bases in the absence of lithium ions.
    • Showcased the facile removal of the phosphazene catalysts via silica gel filtration or aqueous workup.

    Conclusions:

    • The studied nonionic strong bases are effective catalysts for 1,4-addition reactions.
    • The methodology provides a versatile route to functionalized products with good to excellent yields and high stereocontrol.
    • The ease of catalyst removal simplifies purification, making this a practical synthetic approach.